Immage Research Development from 2010 to 2026

IMMG Stock  USD 0.0001  0.00  0.00%   
Immage Biotherapeutics' Research Development is decreasing over the last several years with slightly volatile swings. Research Development is predicted to flatten to about 49.8 K. During the period from 2010 to 2026 Immage Biotherapeutics Corp Research Development regressed destribution of quarterly values had coefficient of variationof  5.38 and r-value of (0.54). View All Fundamentals
 
Research Development  
First Reported
2010-12-31
Previous Quarter
56 K
Current Value
49.8 K
Quarterly Volatility
3.3 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Immage Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immage Biotherapeutics' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 0.0 or Selling General Administrative of 186.3 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 7.0E-4. Immage financial statements analysis is a perfect complement when working with Immage Biotherapeutics Valuation or Volatility modules.
  
Build AI portfolio with Immage Stock
Check out the analysis of Immage Biotherapeutics Correlation against competitors.

Currently Active Assets on Macroaxis

When determining whether Immage Biotherapeutics is a strong investment it is important to analyze Immage Biotherapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Immage Biotherapeutics' future performance. For an informed investment choice regarding Immage Stock, refer to the following important reports:
Check out the analysis of Immage Biotherapeutics Correlation against competitors.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Can Biotechnology industry sustain growth momentum? Does Immage have expansion opportunities? Factors like these will boost the valuation of Immage Biotherapeutics. Market participants price Immage higher when confident in its future expansion prospects. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Immage Biotherapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share
(0.01)
Return On Assets
(4.96)
Return On Equity
(11.34)
Immage Biotherapeutics's market price often diverges from its book value, the accounting figure shown on Immage's balance sheet. Smart investors calculate Immage Biotherapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Immage Biotherapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Immage Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immage Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immage Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.